Jounce Therapeutics Inc. (JNCE) and Anika Therapeutics Inc. (NASDAQ:ANIK) Comparison side by side

This is a contrast between Jounce Therapeutics Inc. (NASDAQ:JNCE) and Anika Therapeutics Inc. (NASDAQ:ANIK) based on their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Jounce Therapeutics Inc. 4 0.00 16.13M -0.82 0.00
Anika Therapeutics Inc. 61 2.82 13.96M 2.05 26.83

In table 1 we can see Jounce Therapeutics Inc. and Anika Therapeutics Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Jounce Therapeutics Inc. 365,759,637.19% -26% -11.7%
Anika Therapeutics Inc. 22,998,352.55% 7.2% 6.7%

Liquidity

The Current Ratio and Quick Ratio of Jounce Therapeutics Inc. are 2.2 and 2.2 respectively. Its competitor Anika Therapeutics Inc.’s Current Ratio is 18.1 and its Quick Ratio is 16.1. Anika Therapeutics Inc. can pay off short and long-term obligations better than Jounce Therapeutics Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for Jounce Therapeutics Inc. and Anika Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Jounce Therapeutics Inc. 0 0 0 0.00
Anika Therapeutics Inc. 1 1 1 2.33

Competitively Anika Therapeutics Inc. has an average price target of $46.33, with potential downside of -19.44%.

Institutional and Insider Ownership

Institutional investors owned 74.2% of Jounce Therapeutics Inc. shares and 96.6% of Anika Therapeutics Inc. shares. About 0.7% of Jounce Therapeutics Inc.’s share are owned by insiders. Insiders Comparatively, owned 0.9% of Anika Therapeutics Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Jounce Therapeutics Inc. 5.97% -2.84% -14.62% 20.65% -32.15% 42.14%
Anika Therapeutics Inc. 34.96% 36.13% 68.01% 45.28% 39.72% 63.91%

For the past year Jounce Therapeutics Inc. was less bullish than Anika Therapeutics Inc.

Summary

Anika Therapeutics Inc. beats on 9 of the 12 factors Jounce Therapeutics Inc.

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. Its lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. The company is also developing JTX-4014, an anti-PD-1 antibody. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The companyÂ’s dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.